Immuneering is a clinical-stage oncology company seeking to develop potential medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Company profile
Ticker
IMRX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Immuneering Securities Corporation • BioArkive, Inc. ...
IMRX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
14 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Results of Operations and Financial Condition
1 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
2 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm |
Cash burn (monthly) | 11.99 mm | 698.13 k | 4.64 mm | 4.67 mm | 4.01 mm | 4.08 mm |
Cash used (since last report) | 71.35 mm | 4.15 mm | 27.62 mm | 27.81 mm | 23.85 mm | 24.26 mm |
Cash remaining | -3.30 mm | 63.89 mm | 40.42 mm | 40.23 mm | 44.19 mm | 43.78 mm |
Runway (months of cash) | -0.3 | 91.5 | 8.7 | 8.6 | 11.0 | 10.7 |
Institutional ownership, Q3 2023
66.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 54 |
Opened positions | 8 |
Closed positions | 4 |
Increased positions | 24 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 101.75 bn |
Total shares | 19.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 4.20 mm | $32.29 bn |
T. Rowe Price | 3.53 mm | $27.14 mm |
BLK Blackrock | 2.51 mm | $19.29 bn |
Merrin Investors | 2.41 mm | $0.00 |
Citadel Advisors | 2.07 mm | $15.87 bn |
Vanguard | 1.04 mm | $8.02 bn |
FMR | 612.17 k | $4.70 bn |
GS Goldman Sachs | 482.93 k | $3.71 bn |
Geode Capital Management | 432.70 k | $3.32 bn |
STT State Street | 361.30 k | $2.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Harold Eugene Brakewood | Class A Common Stock | Buy | Acquire P | No | No | 2.568 | 3,900 | 10.02 k | 3,900 |
22 Mar 24 | Peter Feinberg | Class A Common Stock | Buy | Acquire P | No | No | 2.5485 | 25,000 | 63.71 k | 111,766 |
22 Mar 24 | Thomas J. Schall | Class A Common Stock | Buy | Acquire P | No | No | 2.5465 | 2,900 | 7.38 k | 2,900 |
19 Mar 24 | Benjamin J. Zeskind | Class A Common Stock | Buy | Acquire P | No | No | 2.7663 | 20,000 | 55.33 k | 2,281,852 |
18 Mar 24 | Berman Ann E | Class A Common Stock | Buy | Acquire P | No | No | 2.1295 | 57,965 | 123.44 k | 67,465 |
News
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
27 Mar 24
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
15 Mar 24
Dow Falls Over 200 Points; Adobe Shares Plunge
15 Mar 24
Press releases
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 Mar 24
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
19 Mar 24
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14 Mar 24
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
5 Mar 24
Immuneering Announces Participation in February Investor Conferences
1 Feb 24